Foamix Ltd.

Foamix Pharmaceuticals Ltd.

Pharmos Corporation

Azura Ophthalmics Ltd.

US Government As Represented by the Secretary of the Army

Seanergy Dermatology Ltd.

M.g. Therapeutics, Ltd.

Other

Biomas Inc.

Vyne Therapeutics Inc.

Meda Pharma Sarl

Icdpharma Ltd

Bausch-lomb Incorporated

Novartis Pharma Gmbh

Doron Friedman

Dov Tamarkin

Meir Eini

Shimon Amselem

Alex Besonov

Omer Rafaeli

David Schuz

Tal Berman

Cary J Reich

Yair Alster

Enbal Ziv

Haim Aviv

Kirsten Angela Macfarlane

K Angela Macfarlane

Rita Keynan

Jorge Danziger

Zakhar Nudelman

Joseph Schwartz

Helena Shifrin

George H Lowell

Ella Zlatkis

Yanir Aldouby

Joseph Schwarz

Michael Albeck

Benjamin Sredni

Stefan Hirsch

Nabila Sekkat

Yaacov J Guy

Shimon Anselem

Sabine Meyenburg

Amir Bar-Ilan

Micha Vered

Cary Reich

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Selenium disulfide compositions for use in treating meibomian gland dysfunction

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

Compositions and methods for the treatment of meibomian gland dysfunction

The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.

Compositions comprising sulfated polysaccharides

Described herein are compositions and methods for the increasing the quantity of lipids secreted from meibomian glands. Such compositions and methods are useful for the treatment of meibomian gland dysfunction and disorders resulting therefrom.

Agents for increasing meibomian gland lipid secretion

The present invention teaches a foamable pharmaceutical carrier comprising a benefit agent, selected from the group consisting of a dicarboxylic acid and a dicarboxylic acid ester; a stabilizer selected from the group consisting of at least one surface-active agent; at least one polymeric agent and mixtures thereof; a solvent selected from the group consisting of water, a hydrophilic solvent, a hydrophobic solvent, a potent solvent, a polar solvent, a silicone, an emollient, and mixtures thereof, wherein the benefit agent, stabilizer and solvent are selected to provide a composition that is substantially resistant to aging and to phase separation and or can substantially stabilize other active ingredients. The invention further relates to a foamable composition further containing a liquefied hydrocarbon gas propellant.

Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

The present invention provides self-emulsifying, high concentration and high dose cannabinoid compositions and formulations, to improve administration of cannabinoids and standardized marijuana extracts to patients.

High-strength oral cannabinoid dosage forms

Growing community of inventors

Karmei Yosef, Israel

Doron Friedman